「Pneumococcus」の版間の差分
ナビゲーションに移動
検索に移動
Vaccipedia.admin (トーク | 投稿記録) |
Vaccipedia.admin (トーク | 投稿記録) |
||
25行目: | 25行目: | ||
{|class="wikitable" | {|class="wikitable" | ||
|- | |- | ||
− | !style="width:4em"|Year | + | !style="width:4em" rowspan="2"|Year |
− | !style="width:12em"|PPSV23 | + | !style="width:12em"|PPSV23 |
− | !style="width:12em"|PCV7 | + | !style="width:12em"|PCV7 |
− | !style="width:12em"|PCV13 | + | !style="width:12em"|PCV13 |
− | !style="width:12em"|PCV15 | + | !style="width:12em"|PCV15 |
!style="width:12em"|PCV20 | !style="width:12em"|PCV20 | ||
+ | |- | ||
+ | !Pneumovax NP||Prevenar||Prevenar13||Vaxneuvance|| | ||
|- | |- | ||
!1988<br>昭和63 | !1988<br>昭和63 | ||
36行目: | 38行目: | ||
|- | |- | ||
!2009<br>平成21 | !2009<br>平成21 | ||
− | | ||'''Approved'''<br>- 2mo≤ ≤9yr | + | | ||'''Approved'''<br>- 2mo≤ ≤9yr|| || || |
|- | |- | ||
!2010<br>平成22 | !2010<br>平成22 | ||
− | | ||'''''Routinized'''''<br>- 2mo≤ ≤60mo (<5yr) | + | | ||'''''Routinized'''''<br>- 2mo≤ ≤60mo (<5yr)|| || || |
|- | |- | ||
!2013<br>平成25 | !2013<br>平成25 | ||
− | | ||'''Terminated''' and switched to PCV13||'''Approved'''<br>- 2mo≤ <6yr<br>'''''Routinized'''''<br>- 2mo≤ ≤60mo (<5yr) | + | | ||'''Terminated''' and switched to PCV13||'''Approved'''<br>- 2mo≤ <6yr<br>'''''Routinized'''''<br>- 2mo≤ ≤60mo (<5yr)|| || |
|- | |- | ||
!2014<br>平成26 | !2014<br>平成26 | ||
− | |'''''Routinized'''''<br>- at 65yr<br>- 60-64yr with specific chronic conditions|| ||'''Approved'''<br>- 65yr≤ at risk of IPD | + | |'''''Routinized'''''<br>- at 65yr<br>- 60-64yr with specific chronic conditions|| ||'''Approved'''<br>- 65yr≤ at risk of IPD|| || |
|- | |- | ||
!2020<br>令和2 | !2020<br>令和2 | ||
− | | || ||'''Approved'''<br>- 6yr≤ at risk of IPD | + | | || ||'''Approved'''<br>- 6yr≤ at risk of IPD|| || |
|- | |- | ||
!2022<br>令和4 | !2022<br>令和4 | ||
− | | || || ||'''Approved'''<br>- elderly<br>- adults at risk of IPD | + | | || || ||'''Approved'''<br>- elderly<br>- adults at risk of IPD|| |
|- | |- | ||
!2023<br>令和5 | !2023<br>令和5 | ||
− | | || || ||'''Approved'''<br>- 2mo≤||''Submitted for approval'' | + | | || || ||'''Approved'''<br>- 2mo≤||''Submitted for approval'' |
|- | |- | ||
! !!PPSV23!!PCV7!!PCV13!!PCV15!!PCV20 | ! !!PPSV23!!PCV7!!PCV13!!PCV15!!PCV20 |
2023年8月25日 (金) 15:32時点における版
Navigation Menu |
General issues of Vaccine | |||||||
---|---|---|---|---|---|---|---|
|
General issues of Travel med. | ||||||||
---|---|---|---|---|---|---|---|---|
|
Immunology | |||||||
---|---|---|---|---|---|---|---|
|
Epi & Stats | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Virus | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
COVID-19 | |||||
---|---|---|---|---|---|
|
Bacteria | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Rickettsia | |||||
---|---|---|---|---|---|
|
Protozoa | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Fungi | |||||||
---|---|---|---|---|---|---|---|
|
Nematode (roundworm) | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Trematode (fluke, distoma) | |||||||
---|---|---|---|---|---|---|---|
|
Cestode (tapeworm) | ||||||
---|---|---|---|---|---|---|
|
Medical Zoology | ||||||||
---|---|---|---|---|---|---|---|---|
|
目次
epidemiology
- 1.19mi. deaths in 2016
- 197.05 mil. episodes in 2016
- the leading cause of lower respiratory infections followed by H. influenzae, influenza /B and RS virus
- 50% of pneumococcal deaths in India, Nigeria, DRC and Pakistan
serotype
- all serotypes known more than 90 are pathogenic for human
- differentiation of serotypes is important for epidemiology
antimicrobial resitance
- first reported in late 1960s
Vaccine
- PPSV does not induce T-cell dependent immunity
- PCV induces T-cell dependent immunity
- new product "Pneumosil" from India
- 10-valent
- serotypes 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, 23F
- the reason why PCV13 for older population failed to show persistent efficacy against IPD in the U.S. may be contributed by spread of PCV13 for children which has caused serotype substitutions in community
History of Pneumococcal vaccines in Japan
Year | PPSV23 | PCV7 | PCV13 | PCV15 | PCV20 |
---|---|---|---|---|---|
Pneumovax NP | Prevenar | Prevenar13 | Vaxneuvance | ||
1988 昭和63 |
Approved 2yr≤ Covered by Public Health Insurance - Asplenia |
||||
2009 平成21 |
Approved - 2mo≤ ≤9yr |
||||
2010 平成22 |
Routinized - 2mo≤ ≤60mo (<5yr) |
||||
2013 平成25 |
Terminated and switched to PCV13 | Approved - 2mo≤ <6yr Routinized - 2mo≤ ≤60mo (<5yr) |
|||
2014 平成26 |
Routinized - at 65yr - 60-64yr with specific chronic conditions |
Approved - 65yr≤ at risk of IPD |
|||
2020 令和2 |
Approved - 6yr≤ at risk of IPD |
||||
2022 令和4 |
Approved - elderly - adults at risk of IPD |
||||
2023 令和5 |
Approved - 2mo≤ |
Submitted for approval | |||
PPSV23 | PCV7 | PCV13 | PCV15 | PCV20 |
Table updated on 25th Aug 2023